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Abstract 
Background:  The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing 
the EAACI Guidelines for Allergen Immunotherapy (AIT) for IgE‑mediated food allergy. We seek to critically assess the 
effectiveness, cost‑effectiveness and safety of AIT in IgE‑mediated food allergy.
Methods: We will undertake a systematic review, which will involve searching international biomedical databases 
for published, in progress and unpublished evidence. Studies will be independently screened against pre‑defined 
eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and 
appropriate, quantitatively synthesised.
Discussion: The findings from this review will be used to inform the development of recommendations for EAACI’s 
Guidelines on AIT.
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Background
Food allergy is responsible for considerable morbidity 
and, in some cases, mortality [1]. Epidemiological stud-
ies have demonstrated that the prevalence and severity 
of food allergy may be increasing, particularly in children 
[2–5]. Food allergies can be divided into IgE-mediated 
acute allergic reactions manifesting as urticaria, vomit-
ing, wheezing and anaphylaxis, and non-IgE-mediated 
food allergy which refers to delayed, cell-mediated reac-
tions. This review is focused on IgE-mediated reactions.
Food allergies can be associated with significant reduc-
tion in quality of life, both of individuals who suffer from 
food allergy and their family members [6]. At present, 
avoidance measures are the cornerstone of management 
[7]. Difficulties in avoiding responsible food allergens 
can result in accidental exposure and the risk of trigger-
ing potentially life-threatening anaphylaxis [8]. Many 
individuals with food allergy therefore need to carry 
adrenaline (epinephrine) auto-injectors in order to self-
manage anaphylaxis reactions. This approach is however 
perceived as restrictive and still leaves patients at risk if 
accidental exposure occurs.
Alternative approaches are therefore being investi-
gated. In particular, there is considerable international 
interest in the role of immunotherapy, which involves 
repeated administration of very small, but gradually 
increasing doses of the antigens to which individuals 
are allergic in the hope of allowing safe exposure to the 
foods in question. Allergen immunotherapy (AIT) has, 
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for example, over the last century become established 
clinical practice in relation to the treatment of severe pol-
len, insect venom and drug allergy [9]. However AIT has 
yet to become established in the routine management of 
food allergy.
The European Academy of Allergy and Clinical Immu-
nology (EAACI) is in the process of developing the 
EAACI Guidelines for AIT, and this systematic review is 
one of five inter-linked evidence syntheses that are being 
undertaken in order to provide a state-of-the-art synop-
sis of the current evidence base in relation to evaluating 
AIT for the treatment of food allergy, allergic rhinocon-
junctivitis, venom allergy and allergic asthma, and allergy 
prevention, which will be used to inform the formula-
tion of key clinical recommendations. The focus of this 
review, which builds on our previous related reviews 
[10, 11], is on assessing the effectiveness, safety and cost-
effectiveness of AIT in the management of IgE-mediated 
food allergy.
Methods
Search strategy
A highly sensitive search strategy has been developed, 
and validated study design filters will be applied to 
retrieve articles pertaining to the use of AIT for IgE-
mediated food allergy from electronic bibliographic data-
bases. We have conceptualized the search to incorporate 
the four elements shown in Fig. 1.
To retrieve randomized controlled trials (RCTs), we 
will apply the Cochrane highly sensitive search strategy 
for identifying RCTs in MEDLINE [12]. To retrieve non-
randomised studies, i.e. controlled clinical trials (CCT) 
and quasi-RCTs, we will use the Cochrane Effective 
Practice and Organisation of Care (EPOC) filter Version 
2.4, available on request from the EPOC Group [13, 14]. 
To retrieve case series, we will use the filter developed by 
librarians at Clinical Evidence: http://clinicalevidence.
bmj.com/x/set/static/ebm/learn/665076.html.
We will search the following databases:
  • Cochrane Library including the:
• CENTRAL (Trials)
•  Methods Studies
•  Health Technology Assessments (HTA)
•  Economic Evaluations Database (EED)
  • MEDLINE (OVID)
  • Embase (OVID)
  • CINAHL (Ebscohost)
  • ISI Web of Science (Thomson Web of Knowledge)
  • TRIP Database (www.tripdatabase.com)
  • Clinicaltrials.gov (NIH web).
  • Current controlled trials (www.controlled-trials.com)
  • Australian and New Zealand Clinical Trials Registry 
(http://www.anzctr.org.au)
The search strategy has been developed on OVID MED-
LINE and then adapted for the other databases (see 
Additional file  1: Appendix). In all cases, the databases 
will be searched from inception to March 31, 2016. 
Additional references will be located through searching 
the references cited by the identified studies, and unpub-
lished work and research in progress will be identified 
through discussion with experts in the field. We will 
invite experts who are active in the field from a range 
of disciplines and regions to add to the list of included 
Condion
• IgE-mediated food 
allergy
Intervenons
•AIT administered 
through  sublingual 
(SLIT), oral (OIT) or 
epicutaneous 
(EPIT) routes
•AIT for different 
allergens e.g. milk, 
egg, peanuts and 
tree nuts and 
other foods
Outcomes
•Effecveness
• Safety
•Cost-effecveness
Study designs
•Randomized 
controlled 
trial(RCT) to assess 
effecveness
•Non-randomized 
studies i.e. 
controlled before-
and-aer studies, 
interrupted-me-
series studies and 
controlled clinical 
trials
•Cost-effecveness 
or cost-ulity 
analysis to assess 
health economics
•Case series (>300 
paents) to assess 
safety
Fig. 1 Conceptualization of systematic review of allergen immunotherapy for IgE mediated food allergy
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studies by identifying additional published and unpub-
lished papers and grey literature they are aware of and 
research in progress. We also, will search Web of Sci-
ence to find published conference papers and all three 
major clinical trials repositories [Clinicaltrials.gov (NIH 
web); Current controlled trials (www.controlled-trials.
com); Australian and New Zealand Clinical Trials Reg-
istry (http://www.anzctr.org.au) to identify trials in pro-
gress]. There will be no language restrictions employed; 
where possible, relevant literature will be translated into 
English.
Inclusion criteria
Patient characteristics
We will focus on studies conducted on patients of any age 
with a physician confirmed diagnosis of IgE-mediated 
food allergy to milk, eggs, peanuts, tree nuts and other 
foods in which there is also confirmation of allergic sta-
tus through positive skin prick tests, specific-IgE or food 
challenge tests.
Interventions of interest
This review is focused on AIT for different allergens, i.e. 
milk, eggs, tree nuts, peanuts and other foods, adminis-
tered through the following routes: oral, sublingual and 
epicutaneous.
Comparators
We are interested in studies comparing food allergy AIT 
with placebo or routine care (i.e. adrenaline autoinjector 
with or without antihistamines) or no treatment.
Study designs
RCTs, will be used to investigate effectiveness (i.e. desen-
sitization and tolerance) and impact on disease specific 
quality of life; health economic analysis will be used to 
assess cost-effectiveness; and RCTs and case series with 
a minimum of 300 patients will be used to assess safety. 
We will appraise the evidence by looking at higher lev-
els of evidence such as individual RCTs. However, given 
the likelihood that we will find only a limited number 
of RCTs, we will also search for and include the follow-
ing non-randomized studies (NRS): controlled before-
and-after studies, interrupted-time-series studies and 
controlled clinical trials. Given the high inherent risk of 
bias in making inferences from such NRS, we will be very 
careful in making inferences from these data [15].
Study outcomes
  • Primary Desensitization (i.e. the ability to safely 
consume foods containing the allergen in question 
while on AIT) or tolerance (the ability to consume 
foods containing the allergen in question after dis-
continuing AIT) at food challenge, as defined in the 
relevant studies.
  • Assessment of changes in disease specific quality 
of life using a validated instrument; in making this 
assessment we will focus on the minimal clinically 
important difference change in quality of life [16].
  • Secondary Safety as assessed by local and systemic 
reactions in accordance with the World Allergy 
Organization’s grading system of side-effects [17, 18].
  • Health economic analysis from the perspective of the 
health system/payer as reported in studies.
Exclusion criteria
The following exclusion criteria will be applied:
  • Reviews, systematic reviews, discussion papers, non-
research letters and editorials
  • Animal studies
  • Quantitative studies not employing systematic review 
or RCT, or employing NRS designs other than those 
detailed above
  • Qualitative studies
  • Case series (of <300 patients).
Study selection
All references will be uploaded into the systematic review 
software Distiller and undergo initial deduplication. 
Study titles and abstracts will be independently checked 
by two reviewers according to the above selection crite-
ria and categorized as: included, not included or unsure. 
Calibration will be undertaken after the first 50 screens 
to review any discrepancies between reviewers. For those 
papers in the unsure category, we will retrieve the full-
text and re-categorize as above. Any discrepancies will 
be resolved through discussion and, if necessary, a third 
reviewer will be consulted. Full text copies of potentially 
relevant studies will be obtained and their eligibility for 
inclusion independently assessed. Studies that do not ful-
fil all of the inclusion criteria will be excluded.
Quality assessment strategy
Quality assessments will independently be carried out 
on each study by two reviewers using the relevant qual-
ity assessment tools. Health economic studies will be 
assessed using the relevant CASP tool for economic 
evaluations [19]. RCTs, quasi-RCTs and CCTs will be 
assessed for generation of allocation sequence, conceal-
ment of allocation, baseline outcome measurements, 
baseline characteristics, incomplete outcome data, blind-
ing of outcome assessor, protection against contamina-
tion, selective outcome reporting and other risks of bias. 
The Cochrane Risk of Bias tool will be used for RCTs 
and the Cochrane ACROBAT tool will be used for NRS 
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[12]. Similarly, we will use the quality assessment form 
produced by the National Institute for Health and Clini-
cal Excellence (NICE) to critically appraise case series 
[20]. Any discrepancies will be resolved by discussion 
or, if agreement cannot be reached, a third reviewer will 
arbitrate
Data extraction, analysis and synthesis
Data will be independently extracted onto a custom-
ized data extraction sheet in Distiller by two reviewers, 
and any discrepancies will be resolved by discussion or, 
if agreement cannot be reached, by arbitration by a third 
reviewer.
A descriptive summary with summary data tables will 
be produced to summarize the literature. If clinically and 
statistically appropriate, meta-analysis will be undertaken 
using random-effects modeling given the known clini-
cal heterogeneity between studies. In the event of find-
ing significant statistical heterogeneity between studies 
(assessed using I2), this will initially be visually inspected 
and then, if appropriate, be investigated through the pre-
specified subgroup and sensitivity analyses (see below). 
We will preferentially report on RRs with 95 % CIs A nar-
rative synthesis of the data will also be undertaken.
Sensitivity and subgroup analyses, and assessment 
for publication bias
Sensitivity analyses will be undertaken by comparing the 
findings between RCTs and NRS, and by comparing the 
results from studies that have employed double-blind pla-
cebo controlled food challenges versus those using other 
outcomes to assess for desensitization and/or tolerance.
Subgroup analyses will be undertaken to compare:
  • Children (5–11  years) versus adolescents (12–
17 years) versus adults (≥18 years)
  • Treatment duration: <3 versus ≥3 years
  • Years of follow up: end of treatment, 2 versus 
≥2 years
  • Route of administration: e.g. SCIT versus SLIT
  • Allergens used for AIT
  • Severity of food allergy: mild/moderate versus severe
  • Primary versus secondary IgE-mediated food allergy.
Where possible, publication bias will be assessed through 
the creation of funnel plots, and tested by Egger’s regres-
sion test and Begg’s rank correlation test [21, 22].
Registration and reporting
This review will be registered with the International 
Prospective Register of Systematic Reviews (PROS-
PERO): http://www.crd.york.ac.uk/prospero/. The Pre-
ferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist will be used to guide 
the reporting of the systematic review: http://www.
prisma-statement.org/.
Discussion
This review will involve systematically identifying, criti-
quing and synthesizing the evidence on the effectiveness, 
cost-effectiveness and safety of AIT for the manage-
ment of IgE mediated food allergy. It will build on ear-
lier reviews in this area [10, 11]. The findings from this 
review will be used to inform the development of recom-
mendations for EAACI’s Guidelines on AIT. We antici-
pate that this review will report in 2016.
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